Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pharmicell Co., Ltd.
This long-term follow-up study is a 5-year long-term follow-up study to evaluate long-term safety in Cellgram-CKD subjects. (refer to ClinicalTrials.gov.Identifier: NCT05042206).
The long-term safety of Cellgram-CKD is evaluated by monitoring whether or not an adverse event of special interest (AESI) occurs for 5 years from the date of administration in Cellgram-CKD subjects who voluntarily consented in writing to participate in the long-term follow-up study.
Age
19–79
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Those who participated in the PMC-P-12 clinical trial and received Cellgram-CKD
Subjects who consented in writing to this long-term follow-up study
